代丁是更适合中国HBeAg阴性_1.pptVIP

阿德福韦酯HBeAg阴性乙肝患者长期治疗的明智选择 Evaluation only. Created with Aspose.Slides for .NET 3.5 Client Profile 5.2.0.0. Copyright 2004-2011 Aspose Pty Ltd. Evaluation only. Created with Aspose.Slides for .NET 3.5 Client Profile 5.2.0.0. Copyright 2004-2011 Aspose Pty Ltd. 目录 HBeAg阴性慢乙肝患者需要更加积极的治疗 对HBeAg阴性慢性乙肝患者的治疗建议 阿德福韦酯治疗HBeAg阴性的临床数据 代丁治疗HBeAg阴性临床研究进展 Evaluation only. Created with Aspose.Slides for .NET 3.5 Client Profile 5.2.0.0. Copyright 2004-2011 Aspose Pty Ltd. Evaluation only. Created with Aspose.Slides for .NET 3.5 Client Profile 5.2.0.0. Copyright 2004-2011 Aspose Pty Ltd. HBeAg阴性慢性乙型肝炎所占的比率逐渐提高 意大利、西班牙、希腊的资料表明，HBeAg-慢性乙型肝炎占90%左右； 国内资料显示目前HBeAg阴性乙型肝炎比例为37%-54%1-2 HBeAg阴性CHB所占比率逐渐上升，将成为我国CHB防治的主要挑战 1. Du Heng, et al. J Med Virol 2004 2. Hou JL et al. Chin Med J 2003 3. Hadziyannis. Hepatology 2001 Evaluation only. Created with Aspose.Slides for .NET 3.5 Client Profile 5.2.0.0. Copyright 2004-2011 Aspose Pty Ltd. Evaluation only. Created with Aspose.Slides for .NET 3.5 Client Profile 5.2.0.0. Copyright 2004-2011 Aspose Pty Ltd. 　　　多数HBeAg阴性慢性乙型肝炎疾病进展 HBeAg(-) 慢性乙型肝炎 少数病变轻微,长期稳定,最终疾病恢复 静息期中有多次急性活动 少数静息期逐渐延长,病变最终稳定 多数病变反复活动 多数持续或反复活动,病变进展 近半数肝硬化 又半数肝细胞癌 Luo Kangxian Hepatitis B Basic Biology and Clinical Science Third Edition P467 Evaluation only. Created with Aspose.Slides for .NET 3.5 Client Profile 5.2.0.0. Copyright 2004-2011 Aspose Pty Ltd. Evaluation only. Created with Aspose.Slides for .NET 3.5 Client Profile 5.2.0.0. Copyright 2004-2011 Aspose Pty Ltd. HBeAg阴性患者随着HBV载量升高，肝硬化发生率增加 0 500 1000 1500 2000 2500 3000 HBV DNA (拷贝/mL) 发生率 /100 000 人 - 年 300 – 10 4 10 4 –10 5 10 5 –10 6 ≥ 10 6 300 趋势检验 HBeAg阴性者 p0·001 趋势检验 Evaluation only. Created with Aspose.Slides for .NET 3.5 Client Profile 5.2.0.0. Copyright 2004-2011 Aspose Pty Ltd. Evaluation only. Created with Aspose.Slides for .NET 3.5 Client Profile 5.2.0.0. Copyright 2004-2011 Aspose Pty Ltd. 临床上HBeAg阴性慢性乙型肝炎的特点 基线HBV DNA载量较低 病变常持续低度或间歇性活动 常为肝病中晚期，临床预后较差 抗病毒治疗持